DR. JAMES ROBINSON, MD
Medical Practice at Tulane Ave, New Orleans, LA

6190871, Feb 20, 2001

Mar 11, 1999

9/267941

David D. Ho - Chapaqua NY
James E. Robinson - New Orleans LA

Cedars-Sinai Medical Center - Los Angeles CA

G01N 3353, G01N 33565, G01N 33567, C12Q 300, C12Q 100

435 724

The invention features immunoreagents which neutralize the Human Immunodeficiency Virus Type 1 (HIV-1) by binding to a novel conserved epitope of the HIV-1 gp120. These immunoreagents exhibit a broad neutralizing effect upon HIV attachment to host cells, and are therefore useful in the detection, prevention, amelioration and treatment of HIV disease, primarily AIDS (Acquired Immunodeficiency Syndrome) and ARC (AIDS Related Complex). More particularly, the invention relates to novel human monoclonal antibodies selectively reactive to a conserved conformation dependent determinant of the HIV-1 gp120, derivatives thereof, cell lines that produce these antibodies, and the use of the monoclonal antibodies and their derivatives for the detection, prevention, amelioration and treatment of HIV related disease.

6054284, Apr 25, 2000

Jun 6, 1997

8/870531

David D. Ho - Capaqua NY
James E. Robinson - New Orleans LA

Cedars-Sinai Medical Center - Los Angeles CA
Louisiana State University and Agricultural and Mechanical College
through its Medical Center - New Orleans LA

G01N 3353, G01N 33567, G01N 33537, G01N 33543

435 724

The invention features immunoreagents which neutralize the Human Immunodeficiency Virus Type 1 (HIV-1) by binding to a novel conserved epitope of the HIV-1 gp120. These immunoreagents exhibit a broad neutralizing effect upon HIV attachment to host cells, and are therefore useful in the detection, pervention of HIV disease, primarily AIDS (Acquired Immunodeficiency Syndrome) and ARC (AIDS Related Complex). More particularly, the invention relates to novel human monoclonal antibodies selectively reactive to a conserved conformation dependent determinant of the HIV-1 gp120, derivatives thereof, cell lines that produce these antibodies, and the use of the monoclonal antibodies and their derivatives for the detection, prevention, amelioration and treatment of HIV related disease.

5798251, Aug 25, 1998

May 16, 1991

7/701129

James E. Robinson - New Orleans LA

Cedars-Sinai Medical Center - Los Angeles CA
Louisiana State University and Agricultural and Mechanical College - New Orleans LA

C12N 512, C07K 1610

43524027

The invention features immunoreagents which neutralize the Human Immunodeficiency Virus Type 1 (HIV-1) by binding to a novel conserved epitope of the HIV-1 gp120. These immunoreagents exhibit a broad neutralizing effect upon HIV attachment to host cells, and are therefore useful in the detection, of HIV disease, primarily AIDS (Acquired Immunodeficiency Syndrome) and ARC (AIDS Related Complex). More particularly, the invention relates to novel human monoclonal antibodies selectively reactive to a conserved conformation dependent determinant of the HIV-1 gp120, derivatives thereof, cell lines that produce these antibodies, and the use of the monoclonal antibodies and their derivatives for the detection, prevention, amelioration and treatment of HIV related disease.

8637234, Jan 28, 2014

Apr 8, 2005

11/578761

George M. Shaw - Birmingham AL, US
James E. Robinson - New Orleans LA, US
Frederic Bibollet-Ruche - Birmingham AL, US
Julie M. Decker - Alabaster AL, US
Beatrice H. Hahn - Birmingham AL, US
Peter D. Kwong - Bethesda MD, US

UAB Research Foundation - Birmingham AL
The Administrators of Tulane Educational Fund - New Orleans LA
The United States of America, as represented by the Secretary, Department of Health and Human Services - Washington DC

C12Q 1/70, A61K 39/00, A61K 39/12, A61K 39/21, A61K 39/38, C07K 16/00

435 5, 435339, 4353391, 5303883, 53038835, 4241841, 4241851, 4241861, 4241871, 4241881

Methods and compositions are provided for the use of an envelope polypeptide or a functional variant thereof from a lentivirus that is not HIV-1 as a molecular scaffold for HIV-1 epitopes. The HIV-1 epitopes can be recognized by HIV-1 binding antibodies, HIV-1 neutralizing antibodies and/or CD4-induced antibodies. Thus, methods are provided for detecting HIV-1 binding antibodies in a subject infected with HTV-1. Further provided are methods to determine an epitope for an HIV-1 binding antibody; methods to assay for an HIV-1 binding antibody; methods to identify a soluble CD4 mimic; methods to neutralize an non-HIV-1 virus; diagnostic assays to monitor HIV disease in a subject or to monitor the subject's response to immunization by a HIV vaccine; and methods to alter the neutralization potential of an HIV-1 derived CD4-induced antibody. Chimeric polypeptides, chimeric polynucleotides, kits, cells and viruses are also provided.

6165710, Dec 26, 2000

Apr 30, 1991

7/693055

James E. Robinson - New Orleans LA

C12Q 168, G01N 3353, G01N 33564, G01N 33566

435 5

A process for selectively immobilizing viral glycoproteins on lectin-coated surfaces for use in solid phase immunoassays is disclosed. This method does not require that the virus or antigen be purified prior to immobilization. This method provides an inexpensive and effective immunoassay method to screen fluids for the presence of viral antibodies.